{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:12Z","timestamp":1791404532204,"version":"4.3.3"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alzheimer's Research UK","award":["ARUK-IRG2019B-003"],"award-info":[{"award-number":["ARUK-IRG2019B-003"]}]},{"name":"Alzheimer\u2019s Drug Discovery Foundation and National Institute of Aging","award":["R01AG067926-01"],"award-info":[{"award-number":["R01AG067926-01"]}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/W000865\/1"],"award-info":[{"award-number":["BB\/W000865\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) involves pathological processing of<jats:italic>amyloid precursor protein<\/jats:italic>(<jats:italic>APP<\/jats:italic>) into amyloid-\u03b2 and<jats:italic>microtubule associated protein Tau<\/jats:italic>(<jats:italic>MAPT)<\/jats:italic>into hyperphosphorylated Tau tangles leading to neurodegeneration. Only 5% of AD cases are familial making it difficult to predict who will develop the disease thereby hindering our ability to treat the causes of the disease. A large population who almost certainly will, are those with Down syndrome (DS), who have a 90% lifetime incidence of AD. DS is caused by trisomy of chromosome 21 resulting in three copies of<jats:italic>APP<\/jats:italic>and other AD-associated genes, like dual specificity tyrosine-phosphorylation-regulated kinase 1A (<jats:italic>DYRK1A<\/jats:italic>) overexpression. This implies that DYRK1a inhibitors may have therapeutic potential for DS and AD, however It is not clear how overexpression of each of these genes contributes to the pathology of each disease as well as how effective a DYRK1A inhibitor would be at suppressing any of these. To address this knowledge gap, we used<jats:italic>Drosophila<\/jats:italic>models with human<jats:italic>Tau<\/jats:italic>, human<jats:italic>amyloid-\u03b2<\/jats:italic>or fly<jats:italic>DYRK1A<\/jats:italic>(<jats:italic>minibrain<\/jats:italic>(<jats:italic>mnb<\/jats:italic>)) neuronal overexpression resulting in photoreceptor neuron degeneration, premature death, decreased locomotion, sleep and memory loss. DYRK1A small molecule Type 1 kinase inhibitors (DYR219 and DYR533) were effective at suppressing these disease relevant phenotypes confirming their therapeutic potential.<\/jats:p>","DOI":"10.1038\/s41598-022-19967-y","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T09:03:11Z","timestamp":1663923791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-\u03b2, Tau and DYRK1A neurotoxicity"],"prefix":"10.1038","volume":"12","author":[{"given":"Bangfu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeng","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Dunckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hulme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J. L.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"4","key":"19967_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Alzheimer's disease facts and figures","year":"2016","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement 12(4), 459\u2013509 (2016).","journal-title":"Alzheimers Dement"},{"issue":"6","key":"19967_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8(6), 595\u2013608 (2016).","journal-title":"EMBO Mol. Med."},{"key":"19967_CR3","doi-asserted-by":"crossref","unstructured":"Querfurth, H.W., & LaFerla, F.M. Alzheimer's disease. N. Engl. J. Med. 362 (2010).","DOI":"10.1056\/NEJMra0909142"},{"issue":"6","key":"19967_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ana.410250609","volume":"25","author":"MS Aldrich","year":"1989","unstructured":"Aldrich, M. S. et al. Sleep abnormalities in progressive supranuclear palsy. Ann. Neurol. 25(6), 577\u2013581 (1989).","journal-title":"Ann. Neurol."},{"issue":"10","key":"19967_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00023210-200115100-00004","volume":"15","author":"MV Vitiello","year":"2001","unstructured":"Vitiello, M. V. & Borson, S. Sleep disturbances in patients with Alzheimer\u2019s disease: epidemiology, pathophysiology and treatment. CNS Drugs 15(10), 777\u2013796 (2001).","journal-title":"CNS Drugs"},{"issue":"10","key":"19967_CR6","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.5664\/jcsm.8630","volume":"16","author":"JK Chawla","year":"2020","unstructured":"Chawla, J. K., Burgess, S. & Heussler, H. The impact of sleep problems on functional and cognitive outcomes in children with Down syndrome: A review of the literature. J. Clin. Sleep Med. 16(10), 1785\u20131795 (2020).","journal-title":"J. Clin. Sleep Med."},{"key":"19967_CR7","doi-asserted-by":"crossref","unstructured":"Musiek, E.S., et al., Circadian rest-activity pattern changes in aging and preclinical alzheimer disease. JAMA Neurol. (2018).","DOI":"10.1001\/jamaneurol.2017.4719"},{"issue":"6315","key":"19967_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1126\/science.aah4968","volume":"354","author":"ES Musiek","year":"2016","unstructured":"Musiek, E. S. & Holtzman, D. M. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science 354(6315), 1004\u20131008 (2016).","journal-title":"Science"},{"issue":"2","key":"19967_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neuron.2010.10.013","volume":"68","author":"L Bertram","year":"2010","unstructured":"Bertram, L., Lill, C. M. & Tanzi, R. E. The genetics of Alzheimer disease: Back to the future. Neuron 68(2), 270\u2013281 (2010).","journal-title":"Neuron"},{"issue":"5","key":"19967_CR10","first-page":"595","volume":"13","author":"PJ Dolan","year":"2010","unstructured":"Dolan, P. J. & Johnson, G. V. The role of tau kinases in Alzheimer\u2019s disease. Curr. Opin. Drug Discov. Devel 13(5), 595\u2013603 (2010).","journal-title":"Curr. Opin. Drug Discov. Devel"},{"issue":"2","key":"19967_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.nbd.2005.03.020","volume":"20","author":"I Ferrer","year":"2005","unstructured":"Ferrer, I. et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol. Dis. 20(2), 392\u2013400 (2005).","journal-title":"Neurobiol. Dis."},{"issue":"Pt 3","key":"19967_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt, T., Stieler, J. T. & Holzer, M. Tau and tauopathies. Brain Res. Bull. 126(Pt 3), 238\u2013292 (2016).","journal-title":"Brain Res. Bull."},{"key":"19967_CR13","doi-asserted-by":"crossref","unstructured":"Kellogg, E.H., et al., Near-atomic model of microtubule-tau interactions. Science (New York, N.Y.) 360(6394), 1242\u20131246 (2018).","DOI":"10.1126\/science.aat1780"},{"issue":"4","key":"19967_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris, L. M. et al. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23(4), 213\u2013227 (2010).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"6101","key":"19967_CR15","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1126\/science.1228541","volume":"337","author":"DJ Selkoe","year":"2012","unstructured":"Selkoe, D. J. Preventing Alzheimer\u2019s disease. Science 337(6101), 1488\u20131492 (2012).","journal-title":"Science"},{"key":"19967_CR16","doi-asserted-by":"publisher","first-page":"590896","DOI":"10.3389\/fnmol.2020.590896","volume":"13","author":"Y Soeda","year":"2020","unstructured":"Soeda, Y. & Takashima, A. New insights into drug discovery targeting tau protein. Front. Mol. Neurosci. 13, 590896\u2013590896 (2020).","journal-title":"Front. Mol. Neurosci."},{"issue":"5","key":"19967_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.tig.2006.03.007","volume":"22","author":"E McGowan","year":"2006","unstructured":"McGowan, E., Eriksen, J. & Hutton, M. A decade of modeling Alzheimer\u2019s disease in transgenic mice. Trends Genet. 22(5), 281\u2013289 (2006).","journal-title":"Trends Genet."},{"issue":"4","key":"19967_CR18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1476-5381.2011.01299.x","volume":"164","author":"D Van Dam","year":"2011","unstructured":"Van Dam, D. & De Deyn, P. P. Animal models in the drug discovery pipeline for Alzheimer\u2019s disease. Br. J. Pharmacol. 164(4), 1285\u20131300 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"19967_CR19","doi-asserted-by":"crossref","unstructured":"Buhl, E., Higham, J.P., & Hodge, J.J.L. Alzheimer's disease-associated tau alters Drosophila circadian activity, sleep and clock neuron electrophysiology. Neurobiol. Dis. 104507 (2019).","DOI":"10.1016\/j.nbd.2019.104507"},{"key":"19967_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fnmol.2016.00061","volume":"9","author":"M Cassar","year":"2016","unstructured":"Cassar, M. & Kretzschmar, D. Analysis of amyloid precursor protein function in drosophila melanogaster. Front. Mol. Neurosci. 9, 61 (2016).","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"19967_CR21","first-page":"445","volume":"7","author":"KF Chen","year":"2014","unstructured":"Chen, K. F. et al. The central molecular clock is robust in the face of behavioural arrhythmia in a Drosophila model of Alzheimer\u2019s disease. Dis. Model Mech. 7(4), 445\u2013458 (2014).","journal-title":"Dis. Model Mech."},{"issue":"15","key":"19967_CR22","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.1073\/pnas.0909314107","volume":"107","author":"HC Chiang","year":"2010","unstructured":"Chiang, H. C. et al. PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc. Natl. Acad. Sci. U S A 107(15), 7060\u20137065 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"19967_CR23","doi-asserted-by":"crossref","unstructured":"Higham, J.P., et al., Restoration of olfactory memory in drosophila overexpressing human Alzheimer\u2019s disease associated tau by manipulation of L-Type Ca2+ channels. Front. Cell. Neurosci. 13(409) (2019).","DOI":"10.3389\/fncel.2019.00409"},{"key":"19967_CR24","doi-asserted-by":"crossref","unstructured":"Higham, J.P., et al., Alzheimer\u2019s Disease Associated Genes Ankyrin and Tau Cause Shortened Lifespan and Memory Loss in Drosophila. Frontiers in Cellular Neuroscience, 2019. 13(260).","DOI":"10.3389\/fncel.2019.00260"},{"issue":"7","key":"19967_CR25","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/hmg\/ddu726","volume":"24","author":"K Papanikolopoulou","year":"2015","unstructured":"Papanikolopoulou, K. & Skoulakis, E. M. Temporally distinct phosphorylations differentiate Tau-dependent learning deficits and premature mortality in Drosophila. Hum. Mol. Genet. 24(7), 2065\u20132077 (2015).","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"19967_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1005025","volume":"11","author":"Y Ping","year":"2015","unstructured":"Ping, Y. et al. Linking A\u03b242-Induced Hyperexcitability to Neurodegeneration, Learning and Motor Deficits, and a Shorter Lifespan in an Alzheimer\u2019s Model. PLoS Genet. 11(3), 1\u201325 (2015).","journal-title":"PLoS Genet."},{"issue":"6","key":"19967_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cub.2015.01.016","volume":"25","author":"M Tabuchi","year":"2015","unstructured":"Tabuchi, M. et al. Sleep interacts with abeta to modulate intrinsic neuronal excitability. Curr. Biol. 25(6), 702\u2013712 (2015).","journal-title":"Curr. Biol."},{"issue":"5530","key":"19967_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1062382","volume":"293","author":"CW Wittmann","year":"2001","unstructured":"Wittmann, C. W. et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293(5530), 711\u2013714 (2001).","journal-title":"Science"},{"issue":"10","key":"19967_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1242\/dmm.029728","volume":"10","author":"Y Herault","year":"2017","unstructured":"Herault, Y. et al. Rodent models in Down syndrome research: impact and future opportunities. Dis. Model Mech. 10(10), 1165\u20131186 (2017).","journal-title":"Dis. Model Mech."},{"issue":"6","key":"19967_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1474-4422(10)70112-5","volume":"9","author":"IT Lott","year":"2010","unstructured":"Lott, I. T. & Dierssen, M. Cognitive deficits and associated neurological complications in individuals with Down\u2019s syndrome. Lancet Neurol. 9(6), 623\u2013633 (2010).","journal-title":"Lancet Neurol."},{"key":"19967_CR31","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.12659\/MSM.893377","volume":"21","author":"R Malak","year":"2015","unstructured":"Malak, R. et al. Delays in motor development in children with down syndrome. Med. Sci. Monit. 21, 1904\u20131910 (2015).","journal-title":"Med. Sci. Monit."},{"issue":"11","key":"19967_CR32","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/brainsci11111403","volume":"11","author":"A Lovos","year":"2021","unstructured":"Lovos, A. et al. Circadian sleep-activity rhythm across ages in down syndrome. Brain Sci. 11(11), 1403 (2021).","journal-title":"Brain Sci."},{"issue":"9","key":"19967_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman, F. K. et al. A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 16(9), 564\u2013574 (2015).","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"19967_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ddrr.1128","volume":"18","author":"WB Zigman","year":"2013","unstructured":"Zigman, W. B. Atypical aging in Down syndrome. Dev. Disabil. Res. Rev. 18(1), 51\u201367 (2013).","journal-title":"Dev. Disabil. Res. Rev."},{"key":"19967_CR35","doi-asserted-by":"crossref","unstructured":"O'Leary, L., et al., Early death and causes of death of people with Down syndrome: A systematic review. J. Appl. Res. Intellect. Disabil. (2018).","DOI":"10.1111\/jar.12446"},{"key":"19967_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/bs.apcsb.2016.07.001","volume":"105","author":"LJ Kay","year":"2016","unstructured":"Kay, L. J., Smulders-Srinivasan, T. K. & Soundararajan, M. Understanding the multifaceted role of human down syndrome kinase DYRK1A. Adv. Protein Chem. Struct. Biol. 105, 127\u2013171 (2016).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"19967_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fnbeh.2016.00104","volume":"10","author":"A Duchon","year":"2016","unstructured":"Duchon, A. & Herault, Y. DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome. Front. Behav. Neurosci. 10, 104 (2016).","journal-title":"Front. Behav. Neurosci."},{"key":"19967_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pharmthera.2018.09.010","volume":"194","author":"ML Arbones","year":"2019","unstructured":"Arbones, M. L. et al. DYRK1A and cognition: A lifelong relationship. Pharmacol. Ther. 194, 199\u2013221 (2019).","journal-title":"Pharmacol. Ther."},{"key":"19967_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","volume":"106","author":"S Garcia-Cerro","year":"2017","unstructured":"Garcia-Cerro, S. et al. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer\u2019s disease phenotypes. Neurobiol. Dis. 106, 76\u201388 (2017).","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"19967_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nbd.2005.12.006","volume":"22","author":"KJ Ahn","year":"2006","unstructured":"Ahn, K. J. et al. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 22(3), 463\u2013472 (2006).","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"19967_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/NEN.0b013e318202bfa1","volume":"70","author":"J Wegiel","year":"2011","unstructured":"Wegiel, J. et al. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J. Neuropathol. Exp. Neurol. 70(1), 36\u201350 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Pt 3","key":"19967_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1042\/bj3550609","volume":"355","author":"YL Woods","year":"2001","unstructured":"Woods, Y. L. et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355(Pt 3), 609\u2013615 (2001).","journal-title":"Biochem. J."},{"issue":"1","key":"19967_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2164-11-25","volume":"11","author":"DO Azorsa","year":"2010","unstructured":"Azorsa, D. O. et al. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer\u2019s disease-related tau hyperphosphorylation. BMC Genomics 11(1), 25 (2010).","journal-title":"BMC Genomics"},{"issue":"5","key":"19967_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13000","volume":"18","author":"B Melchior","year":"2019","unstructured":"Melchior, B. et al. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer\u2019s disease. Aging Cell 18(5), e13000 (2019).","journal-title":"Aging Cell"},{"issue":"11","key":"19967_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/cn300094k","volume":"3","author":"B Smith","year":"2012","unstructured":"Smith, B. et al. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer\u2019s?. ACS Chem. Neurosci. 3(11), 857\u2013872 (2012).","journal-title":"ACS Chem. Neurosci."},{"issue":"12","key":"19967_CR46","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.1007\/s12035-019-01684-9","volume":"56","author":"R Velazquez","year":"2019","unstructured":"Velazquez, R. et al. Chronic Dyrk1 inhibition delays the onset of AD-like pathology in 3xTg-AD mice. Mol. Neurobiol. 56(12), 8364\u20138375 (2019).","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"19967_CR47","first-page":"839","volume":"9","author":"H Kim","year":"2016","unstructured":"Kim, H. et al. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Dis. Model Mech. 9(8), 839\u2013848 (2016).","journal-title":"Dis. Model Mech."},{"issue":"8","key":"19967_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002857","volume":"8","author":"SH Hong","year":"2012","unstructured":"Hong, S. H. et al. Minibrain\/Dyrk1a regulates food intake through the Sir2-FOXO-sNPF\/NPY pathway in Drosophila and mammals. PLoS Genet 8(8), e1002857 (2012).","journal-title":"PLoS Genet"},{"key":"19967_CR49","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1038\/ncomms5246","volume":"5","author":"CK Chen","year":"2014","unstructured":"Chen, C. K. et al. Activity-dependent facilitation of Synaptojanin and synaptic vesicle recycling by the Minibrain kinase. Nat. Commun. 5, 4246 (2014).","journal-title":"Nat. Commun."},{"key":"19967_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.nbd.2019.01.017","volume":"125","author":"SA Lowe","year":"2019","unstructured":"Lowe, S. A., Usowicz, M. M. & Hodge, J. J. L. Neuronal overexpression of Alzheimer\u2019s disease and Down\u2019s syndrome associated DYRK1A\/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila. Neurobiol Dis. 125, 107\u2013114 (2019).","journal-title":"Neurobiol Dis."},{"issue":"5","key":"19967_CR51","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/acel.12648","volume":"16","author":"C Branca","year":"2017","unstructured":"Branca, C. et al. Dyrk1 inhibition improves Alzheimer\u2019s disease-like pathology. Aging Cell 16(5), 1146\u20131154 (2017).","journal-title":"Aging Cell"},{"issue":"9","key":"19967_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dmm.035634","volume":"11","author":"TL Nguyen","year":"2018","unstructured":"Nguyen, T. L. et al. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A. Dis. Model Mech. 11(9), 1 (2018).","journal-title":"Dis. Model Mech."},{"key":"19967_CR53","unstructured":"Hulme, C., & Foley, C. Small molecule inhibitors of DYRK\/Clk and uses thereof. US Patent App., 2020. 16\/586,536."},{"key":"19967_CR54","unstructured":"Hulme, C., Shaw, A.Y., & Dunckley, T. Small molecule inhibitors of DYRK1A and uses thereof. US Patent, 2020. 10,730,842."},{"issue":"11","key":"19967_CR55","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.neurobiolaging.2009.10.015","volume":"32","author":"F Kerr","year":"2011","unstructured":"Kerr, F. et al. Dietary restriction delays aging, but not neuronal dysfunction, in Drosophila models of Alzheimer\u2019s disease. Neurobiol. Aging 32(11), 1977\u20131989 (2011).","journal-title":"Neurobiol. Aging"},{"key":"19967_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105752","volume":"170","author":"E Buhl","year":"2022","unstructured":"Buhl, E. et al. Effects of Eph\/ephrin signalling and human Alzheimer\u2019s disease-associated EphA1 on Drosophila behaviour and neurophysiology. Neurobiol. Dis. 170, 105752 (2022).","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"19967_CR57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12035-011-8193-1","volume":"44","author":"K Papanikolopoulou","year":"2011","unstructured":"Papanikolopoulou, K. & Skoulakis, E. M. The power and richness of modelling tauopathies in Drosophila. Mol. Neurobiol. 44(1), 122\u2013133 (2011).","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"19967_CR58","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1523\/JNEUROSCI.1490-09.2010","volume":"30","author":"S Kosmidis","year":"2010","unstructured":"Kosmidis, S. et al. Differential effects of Tau on the integrity and function of neurons essential for learning in Drosophila. J. Neurosci. 30(2), 464\u2013477 (2010).","journal-title":"J. Neurosci."},{"issue":"5","key":"19967_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007383","volume":"14","author":"S Watson-Scales","year":"2018","unstructured":"Watson-Scales, S. et al. Analysis of motor dysfunction in Down Syndrome reveals motor neuron degeneration. PLoS Genet. 14(5), e1007383 (2018).","journal-title":"PLoS Genet."},{"key":"19967_CR60","doi-asserted-by":"crossref","unstructured":"Spires-Jones, T.L., & Hyman, B.T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron. 82 (2014).","DOI":"10.1016\/j.neuron.2014.05.004"},{"key":"19967_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nbscr.2016.09.001","volume":"2","author":"S Dissel","year":"2017","unstructured":"Dissel, S. et al. Enhanced sleep reverses memory deficits and underlying pathology in Drosophila models of Alzheimer\u2019s disease. Neurobiol. Sleep Circadian Rhythms 2, 15\u201326 (2017).","journal-title":"Neurobiol. Sleep Circadian Rhythms"},{"key":"19967_CR62","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fnagi.2019.00320","volume":"11","author":"M Arnes","year":"2019","unstructured":"Arnes, M. et al. Role of tau protein in remodeling of circadian neuronal circuits and sleep. Front Aging Neurosci. 11, 320 (2019).","journal-title":"Front Aging Neurosci."},{"key":"19967_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainres.2010.05.013","volume":"1348","author":"R Sterniczuk","year":"2010","unstructured":"Sterniczuk, R. et al. Characterization of the 3xTg-AD mouse model of Alzheimer\u2019s disease: part 1 Circadian changes. Brain Res. 1348, 139\u2013148 (2010).","journal-title":"Brain Res."},{"key":"19967_CR64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.expneurol.2017.04.015","volume":"294","author":"K Stevanovic","year":"2017","unstructured":"Stevanovic, K. et al. Disruption of normal circadian clock function in a mouse model of tauopathy. Exp. Neurol. 294, 58\u201367 (2017).","journal-title":"Exp. Neurol."},{"key":"19967_CR65","doi-asserted-by":"crossref","unstructured":"Holth, J.K., et al., The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science (2019).","DOI":"10.1126\/science.aav2546"},{"issue":"7","key":"19967_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236318","volume":"15","author":"YY Wang","year":"2020","unstructured":"Wang, Y. Y., Ma, W. W. & Peng, I. F. Screening of sleep assisting drug candidates with a Drosophila model. PLoS ONE 15(7), e0236318 (2020).","journal-title":"PLoS ONE"},{"issue":"2","key":"19967_CR67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/089198879901200203","volume":"12","author":"SM McCurry","year":"1999","unstructured":"McCurry, S. M. et al. Characteristics of sleep disturbance in community-dwelling Alzheimer\u2019s disease patients. J. Geriatr. Psychiatry Neurol. 12(2), 53\u201359 (1999).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"19967_CR68","unstructured":"Vitiello, M.V., Bliwise, D.L., & Prinz, P.N. Sleep in Alzheimer's disease and the sundown syndrome. Neurology 42(7 Suppl 6), 83\u201393 (1992)."},{"issue":"5","key":"19967_CR69","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1176\/appi.ajp.158.5.704","volume":"158","author":"L Volicer","year":"2001","unstructured":"Volicer, L. et al. Sundowning and circadian rhythms in Alzheimer\u2019s disease. Am. J. Psychiatry 158(5), 704\u2013711 (2001).","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"19967_CR70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrn2881","volume":"11","author":"JR Gerstner","year":"2010","unstructured":"Gerstner, J. R. & Yin, J. C. Circadian rhythms and memory formation. Nat. Rev. Neurosci. 11(8), 577\u2013588 (2010).","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"19967_CR71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.expneurol.2009.09.014","volume":"223","author":"J Folwell","year":"2010","unstructured":"Folwell, J. et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer\u2019s disease. Exp. Neurol. 223(2), 401\u2013409 (2010).","journal-title":"Exp. Neurol."},{"issue":"1","key":"19967_CR72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0896-6273(00)80877-6","volume":"25","author":"JC Hendricks","year":"2000","unstructured":"Hendricks, J. C. et al. Rest in Drosophila is a sleep-like state. Neuron 25(1), 129\u2013138 (2000).","journal-title":"Neuron"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19967-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T13:33:11Z","timestamp":1728048791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19967-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19967"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19967-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patents encompassing DYR219 and DYR533 have been in-licensed by Iluminos Therapeutics, founded by the co-authors C.H. and T.D., apart from this potential competing interest these authors have no other competing interests. They did not fund, design, perform or write up any of the experiments performed in the study. B.Z., T.P., Y.S., C.F., and J.J.L.H. have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15847"}}